To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
IntelliCell BioSciences Signed an Exclusive Supply and Sale Agreement with Millipore Corporation
IntelliCell BioSciences, Inc. has announced that it has executed an exclusive supply and sale agreement with Millipore Corporation to sell and distribute the guava® flow cytometry platform into the area of SVF.
This collaboration will streamline the development of IntelliCell's tissue processing centers throughout the United States as it continues to expand and experience growth in demand for the cells it is able to source from fatty tissue.
The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia.
Since the middle of 2009 when the U.S. FDA published its laws on autologous stem cells the field has expanded rapidly.
Currently, numerous doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.
In addition, numerous studies have been conducted on animals for veterinary applications over the last few decades.
"This is a phenomenal step in the right direction for our company and we welcome the opportunity to work with Millipore. The exclusive agreement with Millipore to supply and sell their cutting-edge guava flow cytometer, combined with our proprietary process which has achieved unprecedented yields of stromal vascular fraction without the use of chemical additives such as enzymes, gives us a highly significant advantage in creating the gold standard for the separation of SVF from fat. As the only company to use precise methods of counting cells and checking specimens for cell viability, dead cells, or debris, this is yet another milestone in our quest to become market leader in the area of separation of SVF, which greatly differentiates us from all other companies that manufacture these cells," stated IntelliCell Chairman and CEO, Dr. Steven Victor.
